MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Novo Nordisk A-S

Uždarymo kaina

SektoriusSveikatos priežiūra

67.96 -2.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

67.63

Max

69.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

929M

28B

Pardavimai

14B

86B

P/E

Sektoriaus vid.

21.171

63.778

Pelnas, tenkantis vienai akcijai

6.34

Dividendų pajamingumas

2.33

Pelno marža

32.947

Darbuotojai

76,302

EBITDA

4.2B

40B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+47.13% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.33%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

19B

305B

Ankstesnė atidarymo kaina

70.27

Ankstesnė uždarymo kaina

67.96

Naujienos nuotaikos

By Acuity

39%

61%

134 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Novo Nordisk A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-25 15:33; UTC

Pagrindinės rinkos jėgos

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

2025-02-05 11:53; UTC

Uždarbis

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

2025-02-05 08:19; UTC

Uždarbis

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2025-03-31 12:49; UTC

Rinkos pokalbiai

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

2025-03-28 15:11; UTC

Rinkos pokalbiai

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

2025-03-27 13:45; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

2025-03-24 10:19; UTC

Rinkos pokalbiai

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

2025-03-24 09:08; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

2025-03-19 15:54; UTC

Svarbiausios naujienos

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025-03-11 15:31; UTC

Rinkos pokalbiai

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

2025-03-11 14:58; UTC

Rinkos pokalbiai

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-10 12:00; UTC

Svarbiausios naujienos

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025-02-07 10:30; UTC

Svarbiausios naujienos

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025-02-06 16:16; UTC

Svarbiausios naujienos
Uždarbis

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025-02-06 14:56; UTC

Uždarbis

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025-02-05 13:59; UTC

Uždarbis

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

2025-02-05 12:02; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

2025-02-05 11:35; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

2025-02-05 10:10; UTC

Karštos akcijos

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

2025-02-05 09:43; UTC

Uždarbis

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

2025-02-05 08:47; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

2025-02-05 08:38; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

2025-02-05 08:32; UTC

Uždarbis

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

2025-02-05 08:30; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

2025-02-05 06:46; UTC

Uždarbis

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

2025-02-05 06:45; UTC

Uždarbis

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

2025-02-05 06:43; UTC

Uždarbis

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

2025-02-05 06:42; UTC

Uždarbis

Novo Nordisk: 2025 Capex Expected to be Around DKK65B, Reflecting Expansion of Global Supply Chain

2025-02-05 06:39; UTC

Uždarbis

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints and Related Drug Shortage Notifications

Akcijų palyginimas

Kainos pokytis

Novo Nordisk A-S Prognozė

Kainos tikslas

By TipRanks

47.13% į viršų

12 mėnesių prognozė

Vidutinis 102.17 USD  47.13%

Aukščiausias 124 USD

Žemiausias 90 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

5

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

66.88 / 69.77Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

134 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.